PYPD Stock Forecast: PolyPid Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.09
−7.02% on the day

The 5 Wall Street analysts covering PolyPid Ltd. hold a median 12-month price target of $12 — +97.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 51 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$138.4M
Ticker Nerd rank
51/ 100
Median analyst target
$12
Analysts covering
5
Revenue$0.0
Operating income−$7.8M
Net income−$7.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.7%
1M
+18.3%
YTD
+40.3%
1Y
+67.8%
From 52W high
−7.7%
From 52W low
+69.2%
$3.60
$6.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores PolyPid Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
51/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Momentum
88
Growth
51
Revisions
51
Issuance
51
Value
45
Accruals
21
Quality
16

Volatility (97): The share price has been relatively steady.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PYPD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PYPD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26PYPDHigh $14Median $12Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$9
Low
$12
Median
$14
High

The green dot is the last close — the median target sits +97.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Nov 2026HC Wainwright & Co.ReiteratesBuy$13
27 Oct 2026OppenheimerInitiatesOutperform$10
21 July 2026HC Wainwright & Co.ReiteratesBuy$13
11 Feb 2026HC Wainwright & Co.ReiteratesBuy$13
13 Nov 2025Roth CapitalMaintainsBuy—
14 Aug 2025Craig-HallumMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 June 2025Roth CapitalMaintainsBuy—
17 June 2025JMP SecuritiesMaintainsMarket Outperform—
9 June 2025HC Wainwright & Co.MaintainsBuy—
5 June 2025Roth CapitalInitiatesBuy—
2 June 2025HC Wainwright & Co.AssumesBuy$11
14 Apr 2025HC Wainwright & Co.ReiteratesBuy—
26 Dec 2024HC Wainwright & Co.MaintainsBuy—
16 Dec 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024Craig-HallumInitiatesBuy—
2 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
18 June 2024HC Wainwright & Co.ReiteratesBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PYPD.

Market Radar

This page is one stock. Monday covers all of them.

PYPD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PYPD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, PolyPid Ltd. returned +67.8% against +6.9% for the S&P 500, dividends included.

PYPD vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26PYPDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PYPD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
33.8×

Cheaper than 2% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−309.4%

Higher than 5% of US stocks

Return on assets
−56.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PolyPid Ltd. has a market value of $138.4M and an enterprise value of $124.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$31.5M.

  • Diluted earnings per share, trailing twelve months: −$1.48.

  • Shares outstanding: 19.2M.

  • PolyPid Ltd. employs 69 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

PYPD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PYPDPolyPid Ltd.$138.4M51
MGNXMacroGenics, Inc.$124.6M85
CMPXCompass Therapeutics, Inc.$123.9M29
SIONSionna Therapeutics, Inc.$126.1M21
IVVDInvivyd, Inc.$121.6M22
HUMAHumacyte, Inc.$120.1M15
ZNTLZentalis Pharmaceuticals, Inc.$128.8M44

Take a look at PYPD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own PolyPid Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PYPD

What is the PYPD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering PolyPid Ltd. have a median 12-month price target of $12, with estimates ranging from $8.5 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PYPD stock a buy right now?

Of the 5 analysts covering PolyPid Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PolyPid Ltd. 51 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PYPD?

As at 21 Nov 2026, PolyPid Ltd. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will PYPD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +97.0% from the last close, and Ticker Nerd's factor model ranks PolyPid Ltd. 51 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PYPD stock forecast for 2030?

No analyst covering PolyPid Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYPD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.5 to $14 over the next 12 months.

How has PYPD stock performed over the past year?

PolyPid Ltd. returned +67.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PolyPid Ltd. do?

PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care. Its core platform, PLEX, is used to create controlled-release drug formulations that aim to improve therapeutic performance and address unmet medical needs across surgical care and other specialty areas.

Company

About PolyPid Ltd.

PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care. Its core platform, PLEX, is used to create controlled-release drug formulations that aim to improve therapeutic performance and address unmet medical needs across surgical care and other specialty areas. The company’s lead product candidate, D-PLEX100, is being developed for the prevention of surgical site infections, while its pipeline also includes oncology-focused programs such as OncoPLEX. PolyPid Ltd. works across clinical development, formulation design, and drug delivery technology, positioning itself in the broader market for targeted medicines and advanced pharmaceutical delivery systems. The company is headquartered in Petach Tikva, Israel.

CEO Ms. Dikla Czaczkes Akselbrad · 69 employees · Israel · https://www.polypid.com